Eevia publishes an article on the comparison of bioactivity profiles between Fenoprolic®, Eevia’s pine bark extract, and Pycnogenol®.

Eevia extensively studied the bioactivity of Fenoprolic® and Pycnogenol® with the Eurofins BioMAP® Human Primary Cell Phenotypic profiling platform. The article benchmarks Eevia’s extract against the market leader for OPC extracts from pine bark. The study showed that Eevia’s extract performed nearly identically compared to Pycnogenol® across almost 150 biomarkers. Eurofins tested Fenoprolic® and Pycnogenol® in the same way, on the same biomarkers, and on the same human primary cells, which makes the comparison of the bioactivity profile relevant both in quality and magnitude. Eurofins then compared the bioactivity profiles.

The research article also promotes this form of bioactivity profiling to show bioequivalence between products. It can also identify no equivalence and sort out imposter products, adulterated ingredients, and products with mostly sugar and flavors but little or no bioactive compounds (“Candyceuticals”).